Altogether, these findings demonstrate that stem cell-like CD133/PROM1HIGH patient-derived GBM possess enhanced glycolytic activity compared to their non-stem-like counterparts and targeting glycolysis can suppress the proliferation of stem cell-like GBM tumor subpopulations by promoting cellular senescence. Here, PROM1 is linked to neoplasm.